A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)

Sponsor
GlaxoSmithKline
Study ID
NCT07782996
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • GSK5784283 — DRUG
    GSK5784283 will be administered.
  • Placebo — DRUG
    Placebo will be administered.
  • Standard of care — DRUG
    Standard of care will be administered.

Study Details

The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.

Key Dates

First listed
Aug 24, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
May 4, 2029
Completion
Dec 28, 2029

Study Design

Enrollment
370 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Participants receiving GSK5784283 plus standard of care
  • Placebo Comparator: Participants receiving matching placebo plus standard of care

Primary Outcome Measure

Annualized rate of clinically significant asthma exacerbations [ Time Frame: Up to Week 52 ]

Central Contacts

Find similar trials

Nationwide
Asthma trialsPulmonology trialsLung disease trials

Related Studies